The so called HIV was first reported to be associated with adult T-cell leukaemia endemic is south-western Japan and in the Caribbean.1 They claimed that the virus integrated itself to specific sites in the human genome and activated an onco gene but such integration was later retracted and some researchers claim that the virus integrates into the human genome randomly and not at specific sites. This phenomenon should produce different morphological changes in cells depending on where it integrates itself but this has not been observed. It has been shown that the provirus did not have a common locus of integration in 35 ATL patients and did not integrate on the same chromosome in 2 ATL patients.2
Chronic fatigue is a common symptom associated with AIDS patients especially those suffering from malnutrition. A particular xenotropic MLV named xenotropic murine leukemia virus-related virus (XMRV) has been cloned from human prostate cancer tumors as well as blood samples from individuals suffering from chronic fatigue syndrome (CFS).3 Detection of murine leukemia virus (MLV) DNA in patient samples has suggested that the human population may be infected with murine gammaretroviruses4.
Horizontally transmitted viruses have been etiologically linked to leukemia and lymphoma in several higher mammals (gibbons, cows, and cats). In the best-studied example, the cat, feline leukemia virus is a common community-acquired virus that infrequently produces cancer. However, the infection and its complications (cancer) are not typical of infectious diseases. Epidemilogically, serologically, and virologically, infections with this type of virus can contradict classic infectious disease dogma. Therefore, previous studies that failed to link characteristics of infectious diseases (epidemiologic, serologic, or virologic) to human cancer must be cautiously interpreted.5
Hepatitis can be a serious problem in cancer patients for various reasons. Patients with impaired host defense mechanisms are more likely to develop fulminant infections. During the last decade, it became apparent that community respiratory viruses can cause significant infection in leukemia patients receiving chemotherapy and in bone marrow transplant BMT recipients, accounting for approximately 30% of respiratory infections during the “flu” season. Viral infections are common following BMT, and, to a lesser extent, among patients with leukemia and lymphoma.6
Infections caused by herpes simplex virus (HSV) are the most common viral infections in patients with lymphoma and acute leukemia. These infections occur predominantly in patients with preexistent antibodies to HSV, indicating that most represent reactivation of endogenous latent infection. More than 80% of bone marrow transplant recipients will have reactivation of latent HSV residing in the neuronal ganglia. Lesions caused by HSV are found most often on the lips and oral mucosa. In patients receiving antineoplastic chemotherapy, these lesions tend to become large and painful, and severe mucositis with extensive ulceration of the oral mucosa is not uncommon. Secondary infection with bacteria or fungi may occur.7 Hence, chemotherapy can lead to the development of the AIDS condition.
“About 80% of patients with acute leukemia, 75% of patients with
lymphoma, and 50% of patients with multiple myeloma develop
infection during the course of their disease, and infection is
the proximate cause of death in a substantial fraction of these
patients. Serious infections also occur in patients with solid
tumors in the absence of significant immunosuppression. Multiple
episodes of infection in the same patient are not uncommon. In
severely immunosuppressed patients, the usual signs and symptoms
associated with infection may be altered, suppressed, or even
absent. Therefore, it is often not possible to make a specific
diagnosis, and empiric therapy is generally administered in
high-risk patients who are suspected of having an infection.
Infection continues to be a significant problem in patients with
cancer. Recent advances in medical technology, such as bone
marrow and hematopoietic stem cell transplantation and the use of
intensive chemotherapeutic regimens, have added substantially to
the number of patients who are able to survive neoplastic
disorders but do so with seriously impaired host defense
mechanisms that compromise their ability to resist or contain
Neutropenia remains the most common predisposing factor for infection in cancer patients.9 While some diseases, such as hematologic neoplasms, cause neutropenia, it occurs most often as a result of the myelosuppression caused by antineoplastic chemotherapy, especially when such therapy is administered at doses designed to achieve maximum antitumor activity. The relationship between neutropenia and infection has been studied most extensively in patients with acute leukemia.10 Both the degree and the duration of neutropenia influence the development of infection. Certain drugs used in the treatment of AIDS can also precipitate neutropenia.
Dr. Gallo’s Initial Study On p24
Dr. Gallo’s initial study in cancer patients relates to the glycoprotein p24 which he referred to as a viral specific antigen.
"Circulating immune complexes from two patients with human T-cell leukaemia/ lymphoma virus (HTLV)-related lymphoma were shown to contain the major internal antigen of the virus, p24. The amount of complex-bound p24 in sequential serum samples correlated roughly with tumour cell mass. Small amounts of complex-bound p24 were detected in samples before a relapse became clinically manifest. Measurement of complex-bound p24 in patients with HTLV-associated lymphomas and leukaemias might thus be helpful in management of malignancies ..."11 The scientific community was rather quick and willing to accept DR. Gallo’s findings based on two patients.
The Switch From a Cancer Test to HIV-AIDS Diagnostic Test
Within 2 months of the above publication12, the entire world then went on to embrace the Gallo dogma relating a new virus, he called the HIV as a cause of AIDS at a press conference. And certain pharmaceutical companies rushed in to grab this opportunity. Some began to offer toxic drugs as medication, almost all of which can cause some of the symptoms of AIDS or neutropenia or some form of immune suppression, reflecting a new brilliance of modern medicine.
When they said, "The amount of complex-bound p24 in sequential serum samples correlated roughly with tumour cell mass" and "it might be helpful in the management of malignancies" it related to size of the tumour and they said that it was an antigen of the HIV virus. Well, if that is so, how come this antigen is measured in terms of its concentration using their test kits before handing down a seropositive or seronegative diagnosis? If it was indeed a virus antigen, the diagnosis would be instead based on whether or not this antigen (p24) is present or not. And subsequent researchers have clearly shown that this p24 is not a viral specific protein as it is found in people with many conditions, including those with microparasites, those recovering from flu or malaria and in the malnourished and another researcher has shown that its concentration declines with selenium administration.
As Cal Crilly points13 out, the above publication meant that there was a move in the direction to commercialize the potential use of p24 concentration “in the management of malignancies” but instead that very same approach came to be used to in test kits that hospitals use to hand down an HIV-positive or HIV-negative diagnosis although the disclaimer on these test kits state that “these test kits cannot be used to diagnose AIDS. Use a confirmatory test”! It is so easy to fool the medical fraternity and our politicians.
Bush approved US85 billion for the diagnosis and treatment of AIDS. That money can be better used that to support an open medical fraud. If you can hatch it, you can create a billion dollar industry – fast. The question is – how long will it last?
- Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells. MOTOHARU SEIKI, ROGER EDDY, THOMAS. B. SHOWS & MITSUAKI YOSHIDA. Letters To Nature. Nature 309, 640 - 642 (14 June 1984); doi:10.1038/309640a0
- Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells. MOTOHARU SEIKI, ROGER EDDY*, THOMAS. B. SHOWS* & MITSUAKI YOSHIDA. Letters to Nature. Nature 309, 640 - 642 (14 June 1984); doi:10.1038/309640a0
- Callaway E. 2011. Virology: fighting for a cause. Nature 471:282–285. [PubMed]
- Coffin J. M., Stoye J. P. 2009. A new virus for old diseases? Science 326:530–531. [PMC free article][PubMed]
- Francis DP, Essex M, Leukemia and lymphoma: infrequent manifestations of common viral infections? A review. J Infect Dis. 1978 Dec;138(6):916-23.
- Kenneth V.I. Rolston, MD, FACP and Gerald P. Bodey, MD. Viral Infections. Bookshelf ID: NBK13208
- Kenneth V.I. Rolston, MD, FACP and Gerald P. Bodey, MD. Viral Infections. Bookshelf ID: NBK13208
- Kenneth V I Rolston, MD and Gerald P Bodey, MD. Chapter 157Infections in Patients with Cancer. Bookshelf ID: NBK20904
- Bodey GP. Infections in cancer patients. A continuing association. Am J Med 1986;81 Suppl 1A:11–26.
- Bodey G P, Buckley M, Sathe Y S, Freireich E J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328–340. [PubMed]
- Demonstration of Viral Antigen p24 in Circulating Immune Complexes of Two Patients with Human T-cell Leukemia/ymphoma Virus (HTLV) Positive Lymphoma. Feb 1984http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2884%2990358-1/abstract)
- Cal Crilly, HIV was a Commercial Fraud committed in 1984. http://mitrinchera.obolog.com/hiv-was-commercial-fraud-committed-in-1984r-2254330
13. Cal Crilly, HIV was a Commercial Fraud committed in 1984. http://mitrinchera.obolog.com/hiv-was-commercial-fraud-committed-in-1984r-2254330